A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.

Stephen Leong,S. G. Eckhardt,Emily Chan,Wells A. Messersmith,Jennifer L. Spratlin,D.R. Camidge,Sami G. Diab,Reza Khosravan,Xun Lin,E. Chow Maneval,A. C. Lockhart

A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.

2012

Stephen Leong
S. G. Eckhardt
Emily Chan
Wells A. Messersmith
Jennifer L. Spratlin
D.R. Camidge
Sami G. Diab
Reza Khosravan
Xun Lin
E. Chow Maneval
A. C. Lockhart

Purpose This phase I study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor effects of sunitinib combined with modified FOLFOX6 (mFOLFOX6).

Keywords:

Neutropenia
Oncology
Fluorouracil
FOLFOX
Pharmacology
Tyrosine-kinase inhibitor
Maximum tolerated dose
Tolerability
Surgery
Sunitinib
Internal medicine
Pharmacokinetics
Medicine
phase i study
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations